二甲双胍治疗与子宫内膜癌风险及预后的关联:系统综述与荟萃分析
该系统综述与荟萃分析检索多个数据库至2022年11月,纳入研究评估二甲双胍与2型糖尿病患者子宫内膜癌发病率和死亡率的关系。合并结果显示二甲双胍使用与子宫内膜癌发病率显著升高相关(HR=1.17,95%CI 1.09-1.26,P<0.0001),但可显著降低全因死亡率(HR=0.62,95%CI 0.52-0.74,P<0.00001)和子宫内膜癌特异性死亡率(HR=0.95,95%CI 0.90-1.00,P=0.03),并改善无进展生存期(HR=0.55,95%CI 0.44-0.68,P<0.00001)。
要点
- 二甲双胍使用与2型糖尿病患者子宫内膜癌发病率显著升高相关(HR=1.17,95%CI 1.09-1.26)。
- 二甲双胍可显著降低子宫内膜癌患者全因死亡率(HR=0.62,95%CI 0.52-0.74)。
- 二甲双胍可显著改善2型糖尿病合并子宫内膜癌患者的无进展生存期(HR=0.55,95%CI 0.44-0.68)。
核心结论
- 该荟萃分析未证明二甲双胍有益于预防子宫内膜癌,但二甲双胍可降低2型糖尿病合并子宫内膜癌患者的死亡风险并延长无进展生存时间。
研究设计与样本
- 系统综述与荟萃分析,检索Pubmed、EMBASE、Web of Science、Cochrane Library、SinoMed、CNKI、Wanfang Data和VIP数据库自建库至2022年11月。
- 纳入报告子宫内膜癌发病率数据的研究11项,纳入生存分析的研究17项。
- 结局指标为比较2型糖尿病使用二甲双胍与不使用二甲双胍患者子宫内膜癌发病率和死亡率的风险比(HR)。
- 采用随机或固定效应模型进行数据分析,并进行亚组分析寻找异质性因素。
- 采用推荐分级的评估、制定与评价(GRADE)系统评估证据确定性。
主要发现
- 二甲双胍使用与子宫内膜癌发病率显著升高相关(HR=1.17,95%CI 1.09-1.26,P<0.0001)。
- 二甲双胍可显著降低全因死亡率(HR=0.62,95%CI 0.52-0.74,P<0.00001)。
- 二甲双胍可显著降低子宫内膜癌特异性死亡率(HR=0.95,95%CI 0.90-1.00,P=0.03)。
- 二甲双胍与2型糖尿病合并子宫内膜癌患者无进展生存期显著改善相关(HR=0.55,95%CI 0.44-0.68,P<0.00001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several abstract studies have demonstrated that metformin may be beneficial for preventing and treating endometrial cancer (EC), while the results have been inconsistent and inconclusive. This systematic review and meta-analysis aimed to investigate the association between metformin use and the incidence and mortality of endometrial cancer in diabetic patients. METHODS: A systematic literature search was performed in Pubmed, EMBASE, Web of Science, Cochrane Library, SinoMed, CNKI, Wanfang Data, and VIP from inception to November 2022. The outcome measures were hazard ratios (HRs) comparing the EC incidence and mortality in patients with type 2 diabetes mellitus (T2DM) on metformin and non-metformin. A random or fixed-effects model was applied for data analysis, and subgroup analysis was performed to look for factors of heterogeneity. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) assessed the evidence's certainty. RESULTS: Eleven studies reported data on EC incidence. The pooled results suggested that the use of metformin was associated with a significantly higher incidence of EC (HR = 1.17, 95% CI 1.09-1.26, P < 0.0001). Further, seventeen studies were included for survival analysis. The pooled data showed that metformin could significantly decrease all-cause mortality (HR = 0.62, 95% CI 0.52-0.74, P < 0.00001) and endometrial cancer-specific mortality (HR = 0.95, 95% CI 0.90, 1.00, P = 0.03). Finally, we noted that metformin was associated with significantly improving the progression-free survival (PFS) of EC patients with T2DM (HR = 0.55, 95% CI 0.44, 0.68, P < 0.00001). CONCLUSIONS: This meta-analysis did not prove that metformin was beneficial for preventing EC. However, metformin could reduce their mortality risk and prolong the progression-free survival time of EC patients with T2DM.
引用
- Xie H, Li M, Zheng Y, et al. Associations of metformin therapy treatment with endometrial cancer risk and prognosis: A systematic review and meta-analysis. Gynecol Oncol. 2024. PMID: 38246042. doi:10.1016/j.ygyno.2024.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。